Verastem, Inc. (VSTM) News

Verastem, Inc. (VSTM)

Today's Latest Price: $1.89 USD

0.03 (1.61%)

Updated Jun 1 11:14am

Add VSTM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter VSTM News Items

VSTM News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest VSTM News From Around the Web

Below are the latest news stories about Verastem Inc that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m. EDT.

Yahoo | May 28, 2020

Billionaire Steven Cohen Bets Big on These 3 Stocks

And they’re off to the races. All three of the major U.S. stock indexes popped on Monday after biotech company Moderna reported its experimental COVID-19 vaccine produced encouraging results in its Phase 1 trial, with it appearing to be safe and able to generate an immune response against the virus.While the news has inspired optimism among market watchers, one investing guru is saying slow your roll. Billionaire Steve Cohen told the employees of his investment firm, Point72 Asset Management, to use caution amid the market’s slight rebounds from low points.In a note to his staff, Cohen wrote, “Markets don’t come back in a straight line; after an earthquake there are tremors. We need to continue to be disciplined. We are seeing plenty of opportunities to generate returns, but I don’t wan...

Yahoo | May 19, 2020

Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Zacks Investment Research | May 18, 2020

3 Biotech Stocks Under $4 That Could Surge Over 50%

It has been almost three months since the coronavirus-driven volatility hit the global economy, and the market continues to rapidly move into both the green and the red. Yet, since its March 16 low, the S&P 500 has come a long way, rising nearly 18%. Wall Street pros remind investors that one area of the market has performed significantly better than the S&P 500: the biotech sector. As a result, names inhabiting this space have found themselves under the Street’s microscope.Having said that, there is something to consider when making these investment decisions. Biotech stocks are especially volatile due to the characteristics of the industry itself. For these companies, there are only a few key indicators like study results or regulatory approvals to determine whether or not sustainable...

Yahoo | May 14, 2020

Verastem Oncology Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today reported financial results for the three months ending March 31, 2020, and provided an overview of recent corporate highlights.

Yahoo | May 7, 2020

Why Verastem Stock Is Rising Today

Shares of Verastem (NASDAQ: VSTM) -- a small-cap oncology-focused biotech -- were up by 10.9% as of 2:12 p.m. EDT on Monday. The company has not reported any news, though, so the reason behind that stock market rise is a bit of a mystery. Verastem's stock has been highly volatile all year, and not just because of the coronavirus-fueled market crash.

Yahoo | May 4, 2020

The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual...

Benzinga | May 3, 2020

Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?

Is (VSTM) Outperforming Other Medical Stocks This Year?

Zacks Investment Research | May 1, 2020

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors. The data will be presented as a virtual poster today at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

Yahoo | April 27, 2020

Verastem Oncology Appoints John H. Johnson to its Board of Directors

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that it has appointed John H. Johnson to its Board of Directors. Mr. Johnson’s career covers multiple executive management roles at leading global corporations where he was responsible for overseeing oncology and immunology drug development initiatives and commercialization. Mr. Johnson will serve on the Compensation and Nominating and Governance Committees.

Yahoo | April 23, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6187 seconds.